Pacira Pharma Balance Sheet - Annual (NASDAQ:PCRX)

Add to My Stocks
$47.85 $1.6 (3.46%) PCRX stock closing price Sep 18, 2018 (Closing)

The fundamental analysis of this company requires a thorough look at Pacira Pharma balance sheet. As in our Pacira Pharma stock analysis, analyzing a company also involves looking at the company's assets and liabilities as given in its balance sheet, which can be used to measure financial performance. Annual results announcements include the release of all three financial statements, of which the balance sheet is one. Apart from analyzing Pacira Pharma revenue Pacira Pharma operating cash flow, one needs to check balance sheet items like cash, fixed assets and debt. The Pacira Pharma balance sheet for 2017 shows cash on hand of $54.12M. The company has a debt to equity ratio of 0.98.

View latest 10 year balance sheet data to check Pacira Pharma financial performance.
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Marketable Securities257.22M136.65M101.98M119.13M59.63M30.92M29.98M---
Raw Materials16.5M11.74M16.71M9.26M5.29M4.08M-1.1M--
Work In Progress8.37M11.62M12.15M8.61M6.32M5.97M----
Finished Goods16.54M7.91M32.78M11.38M3.94M2.01M----
Notes Receivable----------
Other Current Assets6.69M9.27M6.11M4.46M2.81M1.92M1.83M-1.07M-
Total Current Assets
Property Plant & Equipment156.25M138.52M115.24M-60.75M50.71M33.38M---
Accumulated Depreciation49.21M37.51M24.91M20.11M12.57M11.6M8.28M---
Net Property Plant & Equipment
Investment & Advances74.19M-13.46M24.43M------
Other Non-Current Assets----------
Deferred Charges----------
Deposits & Other Assets--2.29M2.58M3.4M--2.64M--
Total Assets
Notes Payable--105.92M103.1M98.96M-----
Accounts Payable14.65M7.51M8.73M6.75M3.06M2.56M3.44M6.03M6.99M-
Current Portion Long-Term Debt------7.03M3.18M--
Current Portion Capital Leases----------
Accrued Expenses41.05M36.66M35.37M28.45M17.88M9.79M7.15M3.26M3.47M-
Income Taxes Payable----------
Other Current Liabilities--1.42M1.7M2.02M1.79M14.27M3.84M3.94M-
Total Current Liabilities
Deferred Taxes/Income-7.48M8.08M9.5M3.21M3.72M8.41M19.46M21.56M-
Convertible Debt276.17M108.73M--------
Long-Term Debt-----25.19M18.53M71.66M22.17M-
Non-Current Capital Leases----------
Other Long-Term Liabilities16.49M11.42M11.47M5.4M3.41M3.13M6.35M7.49M8.74M-
Total Liabilities
Minority Interest----------
Preferred Stock----------
Common Stock Net----------
Capital Surplus669.03M565.2M526.69M481.33M337.63M298.31M228.47M88.52M86.8M-
Retained Earnings-389.13M-346.23M-308.28M-310.14M-296.42M-232.52M-180.23M-136.91M-109.76M-
Treasury Stock----------
Other Liabilities-0.45M-0.03M-0.05M-0.08M------
Shareholders Equity279.48M218.97M218.39M171.14M41.24M65.85M48.26M-48.38M-22.94M-
Total Liabilities & Shareholders Equity628.37M391.46M389.62M326.07M169.82M112.05M113.49M66.56M43.95M-
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Looking at Pacira Pharma historical stock prices and the current Pacira Pharma stock price can tell you how the stock price has moved, whereas the Pacira Pharma PE ratio chart shows if its shares are overpriced in comparison to peers. The important things to look for in a balance sheet are:

  • Assets: An asset is a resource that a corporation like Pacira Pharma owns and has economic value. The two major types of assets are: fixed assets like real estate, plant and machinery and current assets like cash, marketable securities and inventory. The total asset value for PCRX stock as of 2017 is $628.37M. Its easy to associate the term with manufacturing companies, which invest a lot in factories and equipment. However, the same cannot be said about tech stocks.
  • Liabilities: This item on the balance sheet implies the firm's, in this case Pacira Pharma's, legal obligations including loans, accounts payable, deferred revenue, accrued expenses and mortgages. The total liabilities for PCRX stock stand at $348.88M.

Pacira Pharma Balance Sheet - Key Ratios

Current ratio
Debt to equity ratio
Asset turnover ratio
Receivables turnover
Price to book ratio